Population-based evidence for the preventative efficacy of quadrivalent HPV in Australia

The HPV vaccination programmes introduced by many countries over the last few years (since 2007) reveal considerable diversity in the coverage they have achieved, the mode of access (i.e. school, public health, private clinics) and responsibility for cost (i.e. publically vv. privately funded) – even in Europe (see ECDC Guidance).  In the light of the […]

Read More…

Missed HPV vaccination opportunities: a consequence of avoiding awkward conversations

In the US, routine administration of quadrivalent HPV vaccine is recommended for girls and boys at 11-12 yrs, with catch-up vaccination recommended up to 26 yrs for girls, and 21 yrs for boys.  The difficulty has been in the implementation of the recommendation: overall rates of initiating and completion among US teenage girls currently stand […]

Read More…